CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 15 enrolled
Drug / intervention
AHES +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02938286
NCT02938286Phase 4Completed

Parameters in Fractional Laser Assisted Delivery of Topical Anesthetics: Role of Laser Type and Laser Settings

Netherlands Institute for Pigment Disorders·interventional·Posted Oct 19, 2016·Updated Mar 29, 2017

In Brief

A Phase 4 clinical trial evaluating Fractional CO2 laser, 2.5 mJ, 5% density, Fractional CO2 laser, 2.5 mJ, 15% density, and 4 other interventions for Local Anesthesia of the Skin. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The purpose of this study is to compare the effect of pretreatment with two different ablative laser modalities, a CO2 laser and an Er:YAG laser, and to assess the role of laser density in fractional laser assisted topical anesthesia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesNetherlands

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 19, 2016
Enrollment StartMar 1, 2016
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 9.7 years ago

Interventions

Fractional CO2 laser, 2.5 mJ, 5% densitydevice

Pretreatment at 2.5 mJ/microbeam and 5% density. Pain stimulus at 50 mJ/microbeam and 5% density

Fractional CO2 laser, 2.5 mJ, 15% densitydevice

Pretreatment at 2.5 mJ/microbeam and 15% density. Pain stimulus at 50 mJ/microbeam and 5% density

Fractional Er:YAG laser, 9 mJ, 5% densitydevice

Pretreatment at 9 mJ and 5% density.

Fractional Er:YAG laser, 9 mJ, 15% densitydevice

Pretreatment at 9 mJ and 15% density.

Fractional CO2 laser, 50 mJ, 5% densitydevice

Pain stimulus at 50 mJ/microbeam and 5% density

AHESdrug

Topical application at test region I-IV under occlusion for 15 minutes